Sign in
Active, not recruitingNo phase

Dual-Modality Immunotherapy for HPV Clearance (DUAL-HPV)

Key facts

Who runs it
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
76 people enrolled
Started
28 Apr 2026
Ended
24 Aug 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Oral Immunomodulator
  • Vaginal Ovule
  • Standard Supportive Care
Record updated
29 July 2026

Who can take part

Age
18 years to 65 years
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Female patients aged 18-65 years
  • Confirmed persistent high-risk human papillomavirus (HR-HPV) infection
  • Histologically confirmed CIN 1 or cytological diagnosis of ASC-US or LSIL
  • Eligible for conservative follow-up without immediate excisional treatment
  • Ability to provide written informed consent and comply with study procedures

Who cannot take part

  • Immunodeficiency or current immunosuppressive therapy
  • Previous treatment for cervical dysplasia within the last 6 months
  • HSIL, CIN2, CIN3, adenocarcinoma in situ, or invasive cervical cancer
  • Known hypersensitivity to any study intervention
  • Pregnancy or breastfeeding
  • Planned colposcopy, cervical biopsy, or LEEP during the 3-month study period
  • Participation in another interventional clinical trial

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Persistent high-risk human papillomavirus infection is an important precursor of cervical cancer and related cervical lesions. This single-center, randomized, assessor-blinded, parallel-group controlled trial evaluates whether dual-modality immunotherapy consisting of an oral immunomodulator plus a vaginal ovule improves HPV clearance compared with standard supportive care. A total of 76 participants will be randomized in a 1:1 ratio. The primary outcome is HPV clearance confirmed by repeat HPV testing and cervical cytology after the 3-month treatment period. Treatment adherence and adverse events will also be monitored.

The 2 groups in the trial

  • Dual-Modality ImmunotherapyTreatment being tested

    Participants receive an oral immunomodulator twice daily together with a vaginal ovule administered for 14 consecutive days each month for 3 months.

    Treatment: Oral Immunomodulator and Vaginal Ovule

  • Standard Supportive CareExisting treatment, for comparison

    Participants receive standard supportive care for 3 months according to routine clinical practice.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Controlled Trial to Evaluate the Efficacy of a Dual-Modality Immunotherapy (Oral Immunomodulator and Vaginal Ovule) for Human Papillomavirus (HPV) Clearance
Record updated
29 July 2026